Kimberly, ScarsiLamorde, MohammedDarin, KristinDilly Penchala, SujanElse, LauraNakalema, ShadiaByakika-Kibwika, PaulineKhoo, SayeCohn, SusanMerry, ConceptaBack, David2022-01-122022-01-122014Scarsi, K., Lamorde, M., Darin, K., Dilly Penchala, S., Else, L., Nakalema, S., ... & Back, D. (2014). Efavirenz‐but not nevirapine‐based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub‐dermal contraceptive implant. Journal of the International AIDS Society, 17, 19484. http://dx.doi.org/10.7448/IAS.17.4.19484http://dx.doi.org/10.7448/IAS.17.4.19484https://nru.uncst.go.ug/xmlui/handle/123456789/1214Sub-dermal hormone implants, such as levonorgestrel (LNG), are a safe and desirable form of long-acting contraception, but their use among HIV-positive women on antiretroviral therapy (ART) may be compromised given the potential for a cytochrome P450 3A-mediated drug-drug interaction. Our study aimed to characterize the pharmacokinetics of LNG released from a sub-dermal implant over six months in HIV-positive Ugandan women on nevirapine (NVP)- or efavirenz (EFV)-based ART.enEfavirenzNevirapine-based antiretroviral therapyLevonorgestrelSub-dermal contraceptive implantArticle